Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46


Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Jul 3. pii: molcanther.0600.2017. doi: 10.1158/1535-7163.MCT-17-0600. [Epub ahead of print]


Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.

Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J, Light M, Lee JS, Debussche L, Sidhu S, Sadreyev RI, Watters J, Engelman JA.

Oncogene. 2017 Nov 23;36(47):6581-6591. doi: 10.1038/onc.2017.258. Epub 2017 Aug 7.


Prostaglandin EP2 receptor signaling protects human trabecular meshwork cells from apoptosis induced by ER stress through down-regulation of p53.

Kalouche G, Boucher C, Coste A, Debussche L, Orsini C, Baudouin C, Debeir T, Vigé X, Rostène W.

Biochim Biophys Acta. 2016 Sep;1863(9):2322-32. doi: 10.1016/j.bbamcr.2016.06.008. Epub 2016 Jun 17.


P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.

Mahfoudhi E, Lordier L, Marty C, Pan J, Roy A, Roy L, Rameau P, Abbes S, Debili N, Raslova H, Chang Y, Debussche L, Vainchenker W, Plo I.

Oncotarget. 2016 May 31;7(22):31980-92. doi: 10.18632/oncotarget.7881.


Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure-Activity Relationships.

Wenzel SC, Hoffmann H, Zhang J, Debussche L, Haag-Richter S, Kurz M, Nardi F, Lukat P, Kochems I, Tietgen H, Schummer D, Nicolas JP, Calvet L, Czepczor V, Vrignaud P, Mühlenweg A, Pelzer S, Müller R, Brönstrup M.

Angew Chem Int Ed Engl. 2015 Dec 14;54(51):15560-4. doi: 10.1002/anie.201508277. Epub 2015 Oct 30.


SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE.

Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16.


Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.

Hoffman-Luca CG, Yang CY, Lu J, Ziazadeh D, McEachern D, Debussche L, Wang S.

PLoS One. 2015 Jun 12;10(6):e0128807. doi: 10.1371/journal.pone.0128807. eCollection 2015.


Discovery, Structure Elucidation, and Biological Characterization of Nannocystin A, a Macrocyclic Myxobacterial Metabolite with Potent Antiproliferative Properties.

Hoffmann H, Kogler H, Heyse W, Matter H, Caspers M, Schummer D, Klemke-Jahn C, Bauer A, Penarier G, Debussche L, Brönstrup M.

Angew Chem Int Ed Engl. 2015 Aug 24;54(35):10145-8. doi: 10.1002/anie.201411377. Epub 2015 Jun 1.


Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.

Hoffman-Luca CG, Ziazadeh D, McEachern D, Zhao Y, Sun W, Debussche L, Wang S.

Clin Cancer Res. 2015 Jun 1;21(11):2558-68. doi: 10.1158/1078-0432.CCR-14-2506. Epub 2015 Mar 9.


SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barrière C, Stuckey JA, Meagher JL, Bai L, Liu L, Hoffman-Luca CG, Lu J, Shangary S, Yu S, Bernard D, Aguilar A, Dos-Santos O, Besret L, Guerif S, Pannier P, Gorge-Bernat D, Debussche L.

Cancer Res. 2014 Oct 15;74(20):5855-65. doi: 10.1158/0008-5472.CAN-14-0799. Epub 2014 Aug 21.


Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma.

Geoerger B, Brasme JF, Daudigeos-Dubus E, Opolon P, Venot C, Debussche L, Vrignaud P, Vassal G.

Eur J Cancer. 2010 Dec;46(18):3251-62. doi: 10.1016/j.ejca.2010.06.005. Epub 2010 Jun 28.


Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.

Wasylyk C, Zheng H, Castell C, Debussche L, Multon MC, Wasylyk B.

Cancer Res. 2008 Mar 1;68(5):1275-83. doi: 10.1158/0008-5472.CAN-07-2674.


CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.

Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Hercend T, Collette M, Robillard N, Bataille R, Amiot M.

J Immunol. 2006 Sep 15;177(6):4218-23.


[Methods for the preclinical screening of new anticancer agents].

Debussche L.

Bull Cancer. 2001 Jan;88(1):67-74. Review. French. No abstract available.


MBP1: a novel mutant p53-specific protein partner with oncogenic properties.

Gallagher WM, Argentini M, Sierra V, Bracco L, Debussche L, Conseiller E.

Oncogene. 1999 Jun 17;18(24):3608-16.


Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains.

Venot C, Maratrat M, Sierra V, Conseiller E, Debussche L.

Oncogene. 1999 Apr 8;18(14):2405-10.


p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.

Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J, Debussche L, Wasylyk B.

Oncogene. 1999 Mar 18;18(11):1921-34.


Calcium-dependent interaction of S100B with the C-terminal domain of the tumor suppressor p53.

Delphin C, Ronjat M, Deloulme JC, Garin G, Debussche L, Higashimoto Y, Sakaguchi K, Baudier J.

J Biol Chem. 1999 Apr 9;274(15):10539-44.


A tumor specific single chain antibody dependent gene expression system.

Mary MN, Venot C, Caron de Fromentel C, Debussche L, Conseiller E, Cochet O, Gruel N, Teillaud JL, Schweighoffer F, Tocque B, Bracco L.

Oncogene. 1999 Jan 14;18(2):559-64.


Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments.

Caron de Fromentel C, Gruel N, Venot C, Debussche L, Conseiller E, Dureuil C, Teillaud JL, Tocque B, Bracco L.

Oncogene. 1999 Jan 14;18(2):551-7.


CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.

Conseiller E, Debussche L, Landais D, Venot C, Maratrat M, Sierra V, Tocque B, Bracco L.

J Clin Invest. 1998 Jan 1;101(1):120-7.


Proteolysis by calpains: a possible contribution to degradation of p53.

Pariat M, Carillo S, Molinari M, Salvat C, Debüssche L, Bracco L, Milner J, Piechaczyk M.

Mol Cell Biol. 1997 May;17(5):2806-15.


Purification of peptide synthetases involved in pristinamycin I biosynthesis.

Thibaut D, Bisch D, Ratet N, Maton L, Couder M, Debussche L, Blanche F.

J Bacteriol. 1997 Feb;179(3):697-704.


Identification and analysis of genes from Streptomyces pristinaespiralis encoding enzymes involved in the biosynthesis of the 4-dimethylamino-L-phenylalanine precursor of pristinamycin I.

Blanc V, Gil P, Bamas-Jacques N, Lorenzon S, Zagorec M, Schleuniger J, Bisch D, Blanche F, Debussche L, Crouzet J, Thibaut D.

Mol Microbiol. 1997 Jan;23(2):191-202.


A Ras-GTPase-activating protein SH3-domain-binding protein.

Parker F, Maurier F, Delumeau I, Duchesne M, Faucher D, Debussche L, Dugue A, Schweighoffer F, Tocque B.

Mol Cell Biol. 1996 Jun;16(6):2561-9.


Biosynthesis of the corrin macrocycle of coenzyme B12 in Pseudomonas denitrificans.

Debussche L, Thibaut D, Cameron B, Crouzet J, Blanche F.

J Bacteriol. 1993 Nov;175(22):7430-40.


Purification and characterization of Cob(II)yrinic acid a,c-diamide reductase from Pseudomonas denitrificans.

Blanche F, Maton L, Debussche L, Thibaut D.

J Bacteriol. 1992 Nov;174(22):7452-4.


The final step in the biosynthesis of hydrogenobyrinic acid is catalyzed by the cobH gene product with precorrin-8x as the substrate.

Thibaut D, Couder M, Famechon A, Debussche L, Cameron B, Crouzet J, Blanche F.

J Bacteriol. 1992 Feb;174(3):1043-9.


Precorrin-6x reductase from Pseudomonas denitrificans: purification and characterization of the enzyme and identification of the structural gene.

Blanche F, Thibaut D, Famechon A, Debussche L, Cameron B, Crouzet J.

J Bacteriol. 1992 Feb;174(3):1036-42.


Purification and partial characterization of Cob(I)alamin adenosyltransferase from Pseudomonas denitrificans.

Debussche L, Couder M, Thibaut D, Cameron B, Crouzet J, Blanche F.

J Bacteriol. 1991 Oct;173(19):6300-2.


A bifunctional protein from Pseudomonas denitrificans carries cobinamide kinase and cobinamide phosphate guanylyltransferase activities.

Blanche F, Debussche L, Famechon A, Thibaut D, Cameron B, Crouzet J.

J Bacteriol. 1991 Oct;173(19):6052-7.


Biosynthesis of vitamin B12: structure of precorrin-6x octamethyl ester.

Thibaut D, Blanche F, Debussche L, Leeper FJ, Battersby AR.

Proc Natl Acad Sci U S A. 1990 Nov;87(22):8800-4.


Assay and purification of S-adenosyl-L-methionine:precorrin-2 methyltransferase from Pseudomonas denitrificans.

Thibaut D, Couder M, Crouzet J, Debussche L, Cameron B, Blanche F.

J Bacteriol. 1990 Nov;172(11):6245-51.


Purification and characterization of cobyrinic acid a,c-diamide synthase from Pseudomonas denitrificans.

Debussche L, Thibaut D, Cameron B, Crouzet J, Blanche F.

J Bacteriol. 1990 Nov;172(11):6239-44.


Genetic and sequence analysis of an 8.7-kilobase Pseudomonas denitrificans fragment carrying eight genes involved in transformation of precorrin-2 to cobyrinic acid.

Crouzet J, Cameron B, Cauchois L, Rigault S, Rouyez MC, Blanche F, Thibaut D, Debussche L.

J Bacteriol. 1990 Oct;172(10):5980-90.


Antibodies to synthetic peptide from the residue 33 to 42 domain of c-Ha-ras p21 block reconstitution of the protein with different effectors.

Rey I, Soubigou P, Debussche L, David C, Morgat A, Bost PE, Mayaux JF, Tocque B.

Mol Cell Biol. 1989 Sep;9(9):3904-10.


Supplemental Content

Loading ...
Support Center